ΔNp63 overexpression, alone and in combination with other biomarkers, predicts the development of oral cancer in patients with leukoplakia

Clinical Cancer Research

Volumn 15, Issue 19, 2009, Pages 6284-6291

  Saintigny, Pierre ^a   El Naggar, Adel K ^a   Papadimitrakopoulou, Vali ^a   Ren, Hening ^a,b   Fan, You Hong ^a   Feng, Lei ^a   Lee, J Jack ^a   Kim, Edward S ^a   Waun, Ki Hong ^a   Lippman, Scott M ^a   Mao, Li ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CAROTENE; ISOTRETINOIN; ONCOPROTEIN; ONCOPROTEIN NP63; PODOPLANIN; RETINOL PALMITATE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; MEMBRANE PROTEIN; PDPN PROTEIN, HUMAN; RETINOL; TP63 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER RISK; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; LEUKOPLAKIA; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; PRIORITY JOURNAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FOLLOW UP; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; INFLAMMATION; MIDDLE AGED; MOUTH TUMOR; PATHOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; UPREGULATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA CAROTENE; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; ISOTRETINOIN; LEUKOPLAKIA, ORAL; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MOUTH NEOPLASMS; PROGNOSIS; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION; VITAMIN A;

EID: 70349659946     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0498     Document Type: Article

References (45)

1. Warnakulasuriya S, Johnson NW, van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med 2007;36:575-580 (Pubitemid 47609807)
2. Papadimitrakopoulou VA, Hong WK, Lee JS, et al. Low-dose isotretinoin versus β- carotene to prevent oral carcinogenesis: long-term follow-up. J Natl Cancer Inst 1997;89:257-258
3. Silverman S, Jr., Gorsky M, Lozada F. Oral leukoplakia and malignant transformation. A follow- up study of 257 patients. Cancer 1984;53: 563-568
4. Lee JJ, Hong WK, Hittelman WN, et al. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res 2000;6:1702-1710
5. Scully C, Porter S. ABC of oral health. Oral cancer. BMJ 2000;321:97-100.
6. Napier SS, Speight PM. Natural history of potentially malignant oral lesions and conditions: an overview of the literature. J Oral Pathol Med 2008;37:1-10.
7. Warnakulasuriya S, Reibel J, Bouquot J, Dabelsteen E. Oral epithelial dysplasia classification systems: predictive value, utility, weaknesses and scope for improvement. J Oral Pathol Med 2008;37:127-133 (Pubitemid 351178405)
8. Lodi GSA, Bez C, Demarosi F, Carrassi A. Interventions for treating oral leukoplakia. Cochrane Database Syst Rev 2006. CD001829.
9. Lippman SM, Heymach JV. The convergent development of molecular-targeted drugs for cancer treatment and prevention. Clin Cancer Res 2007;13:4035-4041
10. Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V, et al. Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol 2008;26:354-360 (Pubitemid 351171684)
11. King KE, Weinberg WC. p63: defining roles in morphogenesis, homeostasis, and neoplasia of the epidermis. Mol Carcinog 2007;46:716-724
12. de Oliveira LR, Ribeiro-Silva A, Zucoloto S. Prognostic impact of p53 and p63 immunoexpression in oral squamous cell carcinoma. J Oral Pathol Med 2007;36:191-197 (Pubitemid 46495983)
13. Lo Muzio L, Campisi G, Farina A, et al. Effect of p63 expression on survival in oral squamous cell carcinoma. Cancer Invest 2007;25:464-469 (Pubitemid 47450678)
14. Lo Muzio L, Santarelli A, Caltabiano R, et al. p63 overexpression associates with poor prognosis in head and neck squamous cell carcinoma. Hum Pathol 2005;36:187-194 (Pubitemid 40313576)
15. Oliveira LR, Ribeiro-Silva A, Costa JP, Simoes AL, Matteo MA, Zucoloto S. Prognostic factors and survival analysis in a sample of oral squamous cell carcinoma patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;106:685-695
16. Bortoluzzi MC, Yurgel LS, Dekker NP, Jordan RC, Regezi JA. Assessment of p63 expression in oral squamous cell carcinomas and dysplasias. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004;98:698-704. (Pubitemid 39610457)
17. Chen YK, Hsue SS, Lin LM. Expression of p63 protein and mRNA in oral epithelial dysplasia. J Oral Pathol Med 2005;34:232-239
18. Takeda T, Sugihara K, Hirayama Y, Hirano M, Tanuma JI, Semba I. Immunohistological evaluation of Ki-67, p63, CK19 and p53 expression in oral epithelial dysplasias. J Oral Pathol Med 2006;35:369-375
19. Papadimitrakopoulou VA, Lee JJ, William WN, Jr., et al. Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without β-carotene in oral premalignancy. J Clin Oncol 2009;27:599-604.
20. Choi HR, Batsakis JG, Zhan F, Sturgis E, Luna MA, El-Naggar AK. Differential expression of p53 gene family members p63 and p73 in head and neck squamous tumorigenesis. Hum Pathol 2002;33:158-164 (Pubitemid 34298729)
21. Khuri FR, Shin DM. Head and neck cancer chemoprevention gets a shot in the arm. J Clin Oncol 2008;26:345-347
22. Thurfjell N, Coates PJ, Uusitalo T, et al. Complex p63 mRNA isoform expression patterns in squamous cell carcinoma of the head and neck. Int J Oncol 2004;25:27-35.
23. Thurfjell N, Coates PJ, Boldrup L, et al. Function and importance of p63 in normal oral mucosa and squamous cell carcinoma of the head and neck. Adv Otorhinolaryngol 2005;62:49-57. (Pubitemid 40014306)
24. Barton CE, Tahinci E, Barbieri CE, et al. ΔNp63 antagonizes p53 to regulate mesoderm induction in Xenopus laevis. Dev Biol 2009;329:130-139
25. Boldrup L, Coates PJ, Gu X, Nylander K. ΔNp63 isoforms regulate CD44 and keratins 4, 6, 14 and 19 in squamous cell carcinoma of head and neck. J Pathol 2007;213:384-391
26. Rocco JW, Leong CO, Kuperwasser N, DeYoung MP, Ellisen LW. p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 2006;9: 45-56. (Pubitemid 43069510)
27. Patturajan M, Nomoto S, Sommer M, et al. ΔNp63 induces β-catenin nuclear accumulation and signaling. Cancer Cell 2002;1:369-379 (Pubitemid 41039138)
28. Chiang CT, Chu WK, Chow SE, Chen JK. Over-expression of ΔNp63 in a human nasopharyngeal carcinoma cell line downregulates CKIs and enhances cell proliferation. J Cell Physiol 2009;219:117-122
29. Yuan P, Temam S, El-Naggar A, et al. Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer 2006;107:563-569 (Pubitemid 44107217)
30. Wicki A, Lehembre F , Wick N, Hantusch B, Kerjaschki D, Christofori G. Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell 2006;9:261-272
31. Wicki A, Christofori G. The potential role of podoplanin in tumour invasion. Br J Cancer 2007;96:1-5. (Pubitemid 46094630)
32. Hackett TL, Shaheen F, Johnson A, et al. Characterization of side population cells from human airway epithelium. Stem Cells 2008.
33. Godar S, Ince TA, Bell GW, et al. Growth-inhibitory and tumor-suppressive functions of p53 depend on its repression of CD44 expression. Cell 2008;134:62-73. (Pubitemid 351905743)
34. Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stemcell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 2007;104:973-978 (Pubitemid 46154721)
35. Yang A, Zhu Z, Kapranov P, et al. Relationships between p63 binding, DNA sequence, transcription activity, and biological function in human cells. Mol Cell 2006;24:593-602. (Pubitemid 350284225)
36. Gannot G, Gannot I, Vered H, Buchner A, Keisari Y. Increase in immune cell infiltration with progression of oral epithelium from hyperkeratosis to dysplasia and carcinoma. Br J Cancer 2002;86:1444-1448 (Pubitemid 34548068)
37. Katou F, Ohtani H, Watanabe Y, Nakayama T, Yoshie O, Hashimoto K. Differing phenotypes between intraepithelial and stromal lymphocytes in early-stage tongue cancer. Cancer Res 2007;67:11195-11201 (Pubitemid 350248544)
38. + T-cell subpopulations in head and neck cancers. Clin Cancer Res 2006;12:465-472
39. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356: 1944-1956 (Pubitemid 46740304)
40. Moro JR, Iwata M, von Andriano UH. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat Rev Immunol 2008;8: 685-698
41. Mao L, Lee JS, Fan YH, et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med 1996;2:682-685 (Pubitemid 26191956)
42. Partridge M, Emilion G, Pateromichelakis S, A'Hern R, Phillips E, Langdon J. Allelic imbalance at chromosomal loci implicated in the pathogenesis of oral precancer, cumulative loss and its relationship with progression to cancer. Oral Oncol 1998;34:77-83. (Pubitemid 28207005)
43. Rosin MP, Cheng X, Poh C, et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res 2000;6:357-362 (Pubitemid 30111451)
44. Eberhard DA, Giaccone G, Johnson BE. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol 2008;26: 983-994
45. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006; 19:264-271 (Pubitemid 43117611)